Sunny Das

Introducing

Ranjan Mishra

Postdoctoral Associate
Ph.D. ETH Zurich, Switzerland
r.mishra@wi.mit.edu

The advent of immune checkpoint blockade therapy has brought a paradigm shift in cancer treatment. In particular, the inhibitory functions of checkpoint proteins, such as PD-1/PD-L1 and CTLA4, are blocked using antibodiesthereby restoring the functions of cytotoxic T cells in eliminating cancer cells. While ICB therapy has been found effective in some cancer such as melanoma, the therapeutic benefits for most of the solid cancers are limited, including notably for ovarian and breast cancer. Using novel syngeneic models of breast and ovarian cancer developed in our lab, I am identifying the determinants of immunotherapy responses in those models. Furthermore, I am determining how such identified factors lead to therapy resistance and developing strategies to intercept their functions in order to potentiate the efficacy of immunotherapy in ovarian and breast cancer.